Wang Xi, Ma Hailu, Wang Fang, Long Hongmei, Li Chenyang, Nie Min, Han Qin, Mao Jiangfeng, Wu Xueyan
NHC Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Clin Endocrinol (Oxf). 2025 Sep;103(3):359-365. doi: 10.1111/cen.15262. Epub 2025 May 27.
Hypothalamic obesity, weight gain dominantly due to hypothalamic dysfunction, is a challenge for patients with craniopharyngioma surgery. Semaglutide, a long-acting GLP-1 receptor agonist, has shown promise in obesity management. However, the efficacy in this specific patient population remains underexplored.
This study aimed to evaluate the efficacy of semaglutide on weight reduction in patients with craniopharyngioma surgery.
A prospective clinical study was conducted involving 23 patients with obesity after craniopharyngioma surgery who attended the outpatient endocrinology department at Peking Union Medical College Hospital from March 2023 to October 2024. Patients were divided into a treatment group receiving semaglutide (n = 14) and a control group undergoing lifestyle intervention alone (n = 9). Parameters including weight, BMI, waist circumference, blood glucose and lipid profiles, were collected at baseline, 3 and 6 months of treatment.
The treatment group showed a significant reduction in weight after 3 months (108.9 ± 20.9 kg vs. 100.8 ± 20.2 kg, p < 0.001) and after 6 months (108.9 ± 20.9 kg vs. 96.1 ± 23.1 kg, p < 0.001). Conversely, the control group experienced weight gain over the same periods. After 3 months, 64.3% of patients in the treatment group achieved weight loss greater than 5%. And after 6 months this rate increased to 90%.
Semaglutide demonstrated significant effects on weight loss in patients with hypothalamic obesity with craniopharyngioma surgery, providing a viable option for managing obesity in this population.
ChiCTR2400094933.
下丘脑性肥胖主要是由于下丘脑功能障碍导致的体重增加，对于颅咽管瘤手术患者来说是一项挑战。司美格鲁肽是一种长效胰高血糖素样肽-1（GLP-1）受体激动剂，在肥胖管理方面已显示出前景。然而，在这一特定患者群体中的疗效仍未得到充分探索。
本研究旨在评估司美格鲁肽对颅咽管瘤手术后患者体重减轻的疗效。
进行了一项前瞻性临床研究，纳入了2023年3月至2024年10月在北京协和医院内分泌门诊就诊的23例颅咽管瘤手术后肥胖患者。患者被分为接受司美格鲁肽治疗的治疗组（n = 14）和仅接受生活方式干预的对照组（n = 9）。在治疗的基线、3个月和6个月时收集体重、体重指数（BMI）、腰围、血糖和血脂谱等参数。
治疗组在3个月后体重显著减轻（108.9±20.9 kg对100.8±20.2 kg，p < 0.001），6个月后体重也显著减轻（108.9±20.9 kg对96.1±23.1 kg，p < 0.001）。相反，对照组在同一时期体重增加。3个月后，治疗组64.3%的患者体重减轻超过5%。6个月后，这一比例增至90%。
司美格鲁肽对颅咽管瘤手术后下丘脑性肥胖患者的体重减轻有显著效果，为该人群的肥胖管理提供了一个可行的选择。
ChiCTR2400094933。
